SPDR S&P Biotech (XBI)

Add to Watchlists
Create an Alert
153.60 -4.67  -2.95% NYSE Arca Sep 22, 2:17PM BATS Real time Currency in USD
View Full Chart
XBI Price Chart

XBI Description

SPDR S&P Biotech is a long only equity fund managed by SPDR State Street Global Advisors that tracks the S&P Biotechnology Select Industry TR USD index and has 1.223B USD assets under management. It has an expected distribution yield of 0.70%, a Prospective PE Ratio of 34.71, and a Prospective Price to Book Value of 4.429. The fund has a net expense ratio of 0.35%, turns over its positions 86.00% per year, and is traded on the New York Stock Exchange Arca.

Benchmark Index: S&P Biotechnology Select Industry TR USD

XBI Key Info

Expense Ratio (6-30-14) 0.35%
Assets Under Management (9-15-14) 1.223B
30-Day Average Volume (9-19-14) 281695.1
Net Asset Value (9-19-14) 158.46
Discount or Premium to NAV (9-15-14) 0.07%
Turnover Ratio (6-30-14) 86.00%

XBI Asset Allocation

Type % Net % Long % Short
Cash 0.17% 0.17% 0.00%
Stock 99.83% 99.83% 0.00%
Bond 0.00% 0.00% 0.00%
Convertible 0.00% 0.00% 0.00%
Preferred 0.00% 0.00% 0.00%
Other 0.00% 0.00% 0.00%
As of Sept. 19, 2014

XBI Region Exposure

Americas 97.47%
North America 97.47%
Latin America 0.00%
Greater Europe 2.53%
United Kingdom 0.00%
Europe Developed 2.53%
Europe Emerging 0.00%
Africa/Middle East 0.00%
Greater Asia 0.00%
Japan 0.00%
Australasia 0.00%
Asia Developed 0.00%
Asia Emerging 0.00%
Market Classification
% Developed Markets 100.0%
% Emerging Markets 0.00%
As of Sept. 19, 2014
Region breakdown data is calculated by using the long position holdings of the portfolio.

XBI Stock Sector Exposure

Basic Materials 0.00%
Communication Services 0.00%
Consumer Cyclical 0.00%
Consumer Defensive 0.00%
Energy 0.00%
Financial Services 0.00%
Healthcare 100.0%
Industrials 0.00%
Real Estate 0.00%
Technology 0.00%
Utilities 0.00%
As of Sept. 19, 2014

XBI Stock Market Capitalization

Giant 5.92%
Large 4.41%
Medium 24.28%
Small 23.14%
Micro 42.07%
As of Sept. 19, 2014
View More Holdings

XBI Top 10 Holdings

Name % Weight Price Chg %
Puma Biotechnology Inc 5.63% 253.60 -6.19%
InterMune Inc 2.05% 73.73 -0.16%
PTC Therapeutics Inc 2.01% 40.47 -1.12%
Receptos Inc 1.97% 60.26 -5.59%
Anacor Pharmaceuticals Inc 1.87% 24.25 -2.26%
United Therapeutics Corp 1.79% 129.58 -0.42%
Vertex Pharmaceuticals Inc 1.75% 103.97 +0.21%
Medivation Inc 1.69% 101.06 -1.17%
Gilead Sciences Inc 1.62% 104.77 -1.12%
Pharmacyclics Inc 1.61% 119.41 -3.33%
As of Sept. 19, 2014
Get Quote for
Advertisement

XBI Risk Info

Beta 1.137
Max Drawdown (1-31-06 to 9-19-14) 37.69%
30 Day Average Volatility 24.65%

XBI Fundamentals

Dividend Yield TTM (9-22-14) 0.70%
Dividend Yield (Prospective) 0.04%
PE Ratio (Prospective) 34.71
PS Ratio (Prospective) 7.289
Price to Book Value (Prospective) 4.429
ROE -20.55%
ROA -23.64%
Number of Holdings 78.00
As of Sept. 19, 2014

XBI Growth Estimates

Forecasted 5 Yr Earnings Growth 19.40%
Forecasted Book Value Growth 9.15%
Forecasted Cash Flow Growth 25.34%
Forecasted Earnings Growth 21.46%
Forecasted Revenue Growth 1.82%
As of Sept. 19, 2014

XBI Performance

  Returns Total Returns
1M -1.87% -1.87%
3M 0.18% 0.58%
6M -5.28% -4.70%
1Y 17.05% 17.88%
3Y 143.0% 145.5%
5Y 174.5% 177.4%
As of Sept. 19, 2014

XBI Flows

1M 16.92M
3M 36.09M
6M -188.19M
YTD 47.64M
1Y 1.853M
3Y 67.93M
5Y 62.41M
As of Aug. 31, 2014
Advertisement

You've hit the 10 page limit on YCharts.

Experience the power of YCharts Professional.
Start your Free 14-Day Trial.

Start My Free Trial No credit card required.

Already a subscriber? Sign in.

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}
Start your free 14 Day Trial.

{{root.upsell.info.button_text}} No credit card required.

Already a subscriber? Sign in.